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Background/aim: To investigate the effects of spermine NONOate in the cavernous tissue obtained from mice treated or untreated with
sildenafil.
Materials and methods: We studied the effects of spermine NONOate on the tone and nitrergic relaxation responses of isolated mouse
corpus cavernosum and compared them with sodium nitroprusside in the absence or presence of L-nitroarginine, hydroxocobalamin,
pyrogallol, diethyldithiocarbamate (DETCA), or 1H-[1,2,4]Oxadiazolo[4,3-a]quinoxalin-1-one (ODQ). The neurogenic contractions
and relaxations of the tissues were induced by electrical field stimulation. Some mice received a single oral dose of sildenafil and after 1
h the effects of spermine NONOate were evaluated by in vitro studies.
Results: Spermine NONOate relaxed mouse corpus cavernosum in a concentration-dependent manner. Spermine-NONOate-induced
relaxation was relatively slow to develop and it was reversible and reproducible. These relaxations were significantly suppressed by
hydroxocobalamin, diethyldithiocarbamate, or ODQ, but not by L-nitroarginine or pyrogallol. Spermine NONOate potentiated the
nitrergic relaxations to electrical field stimulation (EFS), whereas it significantly reduced EFS-induced contractions. Sildenafil treatment
can enhance the relaxant responses to spermine NONOate and EFS.
Conclusion: These findings suggest that spermine NONOate has a potent relaxant action in cavernous tissue and this effect can be
potentiated by oral sildenafil treatments. Spermine NONOate may be considered an attractive treatment for erectile dysfunction in
pathologic disorders with a lack of endogenous NO production.
Key words: EFS, electrical field stimulation, L-NOARG, N-nitro-L-arginine, spermine NONOate, S-NONOate

1. Introduction
It is well known that nitric oxide, which is synthesized by
erectile-autonomic nerves and vascular endothelium of
the cavernous tissue, has an important modulatory role
in penile erection (1). Nitric oxide activates the soluble
guanylate cyclase which catalyzes the biosynthesis of
cyclic guanosine 3’,5’-monophosphate (cGMP). cGMP
causes a relaxation in the cavernous tissue thus eliciting
an erection (1). It is suggested that some pathologic
conditions such as aging and vascular diseases can cause
the impaired synthesis, release, or bioavailability of NO in
the penile tissue (2). Moreover, diabetic neuropathy can
affect nitrergic nerves in the penile tissue (3). This results
in erectile dysfunction due to insufficient relaxation of the
cavernous smooth muscle and dilation of penile arteries.
Phosphodiesterase type 5 (PDE5) inhibitors such as
sildenafil have been very successful in the management of
erectile dysfunction (4,5). It improves erectile function by
* Correspondence: pertug@cu.edu.tr

reducing the breakdown of the active cGMP and causes
potentiation of its action (6). However, diabetic patients
and patients with cavernosal nerve injury following radical
prostatectomy have less success with PDE5 inhibitors than
other patient groups because of a lack of endogenous NO
production (7,8). It is suggested that a residual NO must be
present for a PDE5 inhibitor to be efficient (2). Therefore,
we need novel agents that are combinations of a PDE5
inhibitor and NO-releasing compounds. It is well known
that some prodrugs that contain nitric oxide or nitric
oxide-like species have been used for erectile dysfunction
(8–10).
Recently, it was shown that a nitric oxide donor
S-NONOate elicited smooth muscle relaxation via
stimulating soluble guanylate cyclase (11,12). Since the
molecule of S-NONOate can also generate nitric oxide and
has a long half-life (around 39–73 min), S-NONOate may
be an effective smooth muscle relaxant and vasodilator
(13).
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These properties of S-NONOate suggest that it can
potentially be used for treatment of erectile dysfunction
that has been attributed in part to a lack of endogenous
nitric oxide production (2). Mouse corpus cavernosum
has been used previously for in vivo and in vitro studies
of erectile mechanisms (14–18). Therefore, in the present
study, we aimed to demonstrate the pharmacological
effects of S-NONOate in the mouse cavernous tissue.
We further analyzed the effect of S-NONOate on the
tone and nitrergic relaxation responses of isolated mouse
corpus cavernosum and compared the effects with those
of a PDE5 inhibitor, sildenafil, and an NO donor, sodium
nitroprusside (SNP).
2. Materials and methods
2.1. Animals
Male Swiss albino mice (n = 50) weighing 25–30 g were
used throughout the experiments. The experimental
procedure was approved by the animal care committee
of the University of Çukurova (TIBDAM) and the
experiments were carried out in accordance with the
Principles of Laboratory Animal Care (National Institute
of Health guideline; publication No. 86–23, revised 1984).
All animals were kept under laboratory conditions (12 h
dark/12 h light) and allowed access to food and drink ad
libitum.
2.2. Organ bath experiments
The mice were killed by cervical dislocation. Penises were
removed and placed in a petri dish containing Krebs’
solution (composition mM: NaCl 119, KCl 4.6, CaCl2 1.5,
MgCl2 1.2, NaHCO3 15, NaHPO4 1.2, glucose 11). Corpus
cavernosum was prepared according to the previously
described method (15). The preparations were mounted
under 0.2-g tension in a 15-mL organ bath maintained
at 37 °C containing Krebs’ solution aerated with 95% O2
and 5% CO2. The tissue was allowed to equilibrate for 1 h.
During this period, the preparation was washed with fresh
Krebs’ solution at 15-min intervals. The responses were
recorded on a polygraph (Ugo Basile, Gemini 7070) via an
isotonic transducer (Ugo Basile, 7006).
After the equilibration period, the tissue was treated
with 5 µM of phenylephrine. The active tone reached
a stable level within 5 min; at the end of this period,
S-NONOate (0.1, 0.3, 1, 3, 10, 30, and 100 µM) or SNP
(0.1, 0.3, 1, 3, and 10 µM) was applied cumulatively on
the different preparations of corpus cavernosum. Thus,
the first series of responses were obtained. After the 30
min washout period, the second series of responses were
recorded in a similar manner. In some experiments, after
the first series of responses were recorded, we examined the
relaxant responses of S-NONOate on the phenylephrine
(5 µM)-induced contractions in the presence of N -nitroL-arginine (L-NOARG; a nitric oxide synthase inhibitor;
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100 µM), hydroxocobalamin (a nitric oxide-binding agent;
100 µM), pyrogallol (a superoxide anion generator; 10
µM), DETCA (a superoxidase inhibitor; 8 mM), or ODQ
(a selective soluble guanylate cyclase inhibitor; 2 µM). In
another experimental group, the relaxant effect of SNP was
examined on the contracted tissue by phenylephrine in the
presence of 8 mM DETCA or 2 µM ODQ. The incubation
period for all antagonists and inhibitors was 30 min.
In some groups, a PDE5 inhibitor sildenafil (30 mg/
kg) was given to mice via a stomach tube in a volume of
0.3 mL 1 h before the experiments. Then we examined
the S-NONOate-induced relaxations (0.1–100 µM) on the
contractions to phenylephrine to test possible interactions
between S-NONOate and sildenafil. In these series, at the
end of the experiments, the tissue was contracted with
phenylephrine once more to monitor the papaverine (100
µM) relaxation.
In experiments in which electrical field stimulation
(EFS) was used, atropine (1 µM) and guanethidine (1
µM) were always present in the bathing medium to
inhibit cholinergic and adrenergic responses. After the
equilibration period, the tissue was treated with 5 µM
of phenylephrine. The active tone reached a stable level
within 5 min; at the end of this period, EFS (2, 4, 8, 16,
and 32 Hz: 30 V, 0.5 ms) was applied to the tissue for
15 s by a Grass S88 stimulator via 2 parallel platinum
electrodes embedded in Perspex. We used the same EFS
parameters in our previously published papers (11,15).
Thus, the first series of responses were obtained. After a
30-min washout period, the second series of responses
were recorded in a similar manner. In some experiments,
after the first series of responses were recorded, the tissues
were incubated with S-NONOate (1 and 5 µM) for 30 min
and then the second series of relaxation responses to EFS
were examined. In another group, we evaluated the effect
of S-NONOate on the neurogenic contractile responses to
EFS (2, 4, 8, 16, and 32 Hz: 30 V, 0.5 ms) in the presence
of L-NOARG (100 µM). In these experiments, L-NOARG
was always present in the bathing medium to inhibit nitric
oxide synthase enzyme. After we obtained the first series
of EFS-induced contractile responses, we examined the
effect of S-NONOate on these contractions to EFS. The
incubation period of spermine NONOate was 30 min.
2.3. Drugs and solutions
Stock solutions of phenylephrine, hydroxocobalamin,
pyrogallol, papaverine, SNP, spermine NONOate,
diethyldithiocarbamate (DETCA), NG-nitro-L-arginine,
guanethidine, and atropine sulfate were dissolved in
distilled water. 1H-[1,2,4]Oxadiazolo[4,3-a]quinoxalin1-one (ODQ) was dissolved in dimethyl sulfoxide (final
concentration in the bath medium was 0.1%). The
S-NONOate stock solution was stored at 20 °C. Except
for sildenafil citrate, all drugs were obtained from Sigma.
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Sildenafil citrate (Sildegra 50 mg tablet, Fako) was
purchased from a drugstore.
2.4. Statistical analysis
Relaxations were expressed as a percentage of the
phenylephrine-induced contraction. In the experiments
that used sildenafil, relaxations to S-NONOate were
expressed as a percentage of the papaverine-induced
relaxation. All data were expressed as mean ± SE. All data
were evaluated with the paired and unpaired student-t
tests that were used in analysis of variance. P values less
than 0.05 are considered significant. Statistical analysis
was performed with GraphPad Prism software (San Diego,
CA, USA).
3. Results
3.1. Relaxant effects of S-NONOate or SNP in mouse
corpus cavernosum
S-NONOate (0.1–100 µM) or SNP (0.1–10 µM) relaxed
mouse corpus cavernosum in a concentration-dependent
manner (Figure 1). S-NONOate-induced relaxation was
relatively slow to develop, whereas SNP-induced relaxation
developed very rapidly. S-NONOate-induced relaxation
was reversible and reproducible (Figure 2).
3.2. Effect of L-NOARG or ODQ on relaxation to
S-NONOate or SNP in mouse corpus cavernosum
L-NOARG (100 µM) did not alter the relaxation to
S-NONOate (0.1–100 µM; Table 1) or SNP (0.1–10
µM; data not shown), whereas 2 µM ODQ significantly
decreased the relaxations to S-NONOate or SNP at all
concentrations (Tables 1 and 2). Thus, both S-NONOate
and SNP were apparently endothelium-independent
vasorelaxants directly stimulating smooth muscle soluble
guanylate cyclase in the cavernosal tissue. The solvent
(DMSO; 0.1%) of ODQ had no effect on the responses
to S-NONOate (Table 1). DETCA (8 mM) also inhibited
the relaxations to SNP (0.1–100 µM; Table 2). 100 µM
hydroxocobalamin exhibited a similar inhibition on the
relaxations to SNP (0.1–100 µM) (% inhibition: 89.5 ± 7.9
at 1 µM SNP).

A

3.3. Effect of hydroxocobalamin, pyrogallol, or DETCA
on relaxation to S-NONOate or SNP in mouse corpus
cavernosum
Incubation of the tissue with pyrogallol (100 µM) did not
significantly affect relaxations evoked by S-NONOate (0.1–
100 µM; Table 1) or SNP (0.1–10 µM; data not shown). On
the other hand, hydroxocobalamin (100 µM) or DETCA
(8 mM) caused significant inhibition of relaxation to
S-NONOate (0.1–100 µM) or SNP (0.1–10 µM) (Tables 1
and 2).
3.4. Effect of S-NONOate or SNP on relaxations or
contractions induced by electrical field stimulation in
mouse corpus cavernosum
EFS (2–32 Hz; 30 V; 0.5 ms) elicited reproducible frequencydependent relaxation responses that were completely
inhibited in the presence of L-NOARG (100 µM) and ODQ
(2 µM) (% inhibitions were 99 ± 3.1 and 98 ± 2.2 at 4 Hz
for L-NOARG and ODQ, respectively). S-NONOate (1–5
µM) enhanced the magnitude of relaxation responses at
all frequencies (2–16 Hz) in the tissue precontracted with
phenylephrine concentration dependently (Table 3). SNP
also caused an increase in some of the relaxations to EFS,
but these enhancements were not statistically significant
(not shown). On the other hand, S-NONOate (1 µM) or
SNP (1 µM) significantly inhibited contraction to EFS
(2–16 Hz) in the presence of 100 µM L-NOARG (Table 4;
results obtained with SNP not shown).
3.5. Relaxant effects of S-NONOate or EFS in mouse
corpus cavernosum after administration of a single oral
dose of sildenafil
Relaxations induced by S-NONOate (0.1–100 µM) in
mouse cavernosum precontracted with phenylephrine (5
µM) were significantly higher compared to the control
group after a single oral dose (30 or 60 mg/kg) of sildenafil
(Figure 3). Moreover, relaxations to EFS were significantly
higher in the tissues of mice treated with sildenafil (30 or
60 mg/kg) than in those of the control group (Table 5).

B

Figure 1. Representative tracings showing the relaxant effects of (A) S-NONOate
(0.1–100 µM) and (B) SNP (0.1–10 µM) in mouse corpus cavernosum. ‘w’ represents
washout.
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this relaxation can be due in part to the generation of nitric
oxide from S-NONOate and also by direct activation of
soluble guanylate cyclase by S-NONOate via a nitric oxidedependent mechanism. Another important finding of the
present study is that oral sildenafil treatment potentiated
the relaxations to S-NONOate.
Spermine NONOate caused a relaxation resembling the
effect of SNP and the S-NONOate action developed slowly.
In the present study, the ineffectiveness of L-nitroarginine
on responses to S-NONOate suggests that an endogenous
L-arginine/nitric oxide pathway has minor importance
in the mechanism of S-NONOate-induced relaxation.
Furthermore, ODQ could inhibit the relaxant responses to
both S-NONOate and SNP. This finding suggests that the
relaxant activity of S-NONOate is mainly due to stimulation
of soluble guanylate cyclase in the cavernous smooth
muscle cells. Although there are some studies that suggest
that S-NONOate can produce cyclic GMP-independent
relaxation in some tissues such as rat pulmonary and
femoral arteries (19,20), it appears that most of the effects
of S-NONOate are due to direct nitric oxide-dependent
interaction of S-NONOate with soluble guanylate cyclase,
which enhances cGMP synthesis in this tissue.

0

% Relaxation

20
40
60
First Series

80
100

Second Series
–7

–6

–5

–4

Log [S–NONOate]

Figure 2. The reversible and reproducible effects of S-NONOate
(0.1–100 µM) in the mouse corpus cavernosum. Results are
expressed as mean ± SE (n = 6–8).

4. Discussion
The results of the present study suggest that S-NONOate
induces relaxation of the mouse corpus cavernosum and the
relaxant activity of S-NONOate is mediated predominantly
by stimulation of soluble guanylate cyclase similar to the
effect of S-NONOate in other tissues. Our data show that

Table 1. The effects of DMSO (0.1%), DETCA (8 mM), L-NOARG (100 µM), ODQ (2 µM), pyrogallol (10 µM), and hydroxocobolamin
(HC; 100 µM) on relaxations of S-NONOate of isolated mouse corpus cavernosum contracted by 5 µM phenylephrine.
S-NONOate

0.1

0.3

1

3

10

30

100 µM

CONTROL

5.3 ± 0.4

13.0 ± 1.2

22.0 ± 1.5

46.0 ± 3.2

67.0 ± 3.1

86.0 ± 2.9

94.0 ± 0.5

DMSO

4.9 ± 0.3

11.2 ± 0.9

21.3 ± 1.2

43.8 ± 2.7

64.3 ± 1.9

82.9 ± 3.1

89.5 ± 2.5

DETCA

0.5 ± 0.3*

8.2 ± 1.4*

9.9 ± 1.7*

36.0 ± 3.5*

55.0 ± 5.8*

77.0 ± 3.7

88.0 ± 3.5

L-NOARG

4. 6 ± 0.9

8.5 ± 1.9

180 ± 2.5

42.0 ± 4.9

63.0 ± 4.4

80.0 ± 2.8

89.0 ± 2.1

ODQ

0.58 ± 0.6*

3.5 ± 1.3*

5.3 ± 1.7*

24.0 ± 3.1*

36.0 ± 6.5*

63.0 ± 4.2*

79.0 ± 3.0*

PYROGALLOL

5.3 ± 1.4

11.0 ± 1.7

17.0 ± 3.6

38.0 ± 3.0

58.0 ± 3.5

76.0 ± 5.3

85.0 ± 6.40

HC

1.9 ± 0.2*

4.9 ± 0.7*

8.28 ± 0.7*

18.9 ± 1.3*

33.3 ± 1.2*

54.5 ± 2.8*

68.0 ± 4.6*

The results are presented as the percentage of the maximal response to phenylephrine-induced contraction at the end of each experiment
(mean ± SE, n = 6). *P < 0.05 shows significant difference from control responses before drug application.
Table 2.The effects of DETCA (8 mM) and ODQ (2 × 10–6 M) on relaxations of SNP of isolated
mouse corpus cavernosum induced by phenylephrine.
SNP

0.1

0.3

1

3

10 µM

CONTROL

7.3 ± 4.0

25 ± 7.6

47.8 ± 6.6

69.8 ± 4.2

74.4 ± 4.8

DETCA

1.8 ± 1.9*

3.6 ± 3.6*

14.4 ± 7.0*

29.3 ± 9.9*

41.9 ± 12.0*

ODQ

1.43 ± 1.0*

6.3 ± 2.3*

12.5 ± 4.3*

38.3 ± 15.1*

47.1 ± 15*

The results are presented as the percentage of the maximal response to phenylephrine-induced
contraction at the end of each experiment (mean ± SE, n = 6). *P < 0.05 shows significant
difference from control responses before drug application.
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Table 3. The potentiated effects of S-NONOate on the relaxations to EFS (2–32 Hz, 50 V, 0.5 ms) in
mouse corpus cavernosum.
EFS

2

4

8

16

32 Hz

Control

18.96 ± 2.40

28.70 ± 2.80

38.34 ± 2.24

45.75 ± 1.77

35.72 ± 2.80

S-NONOate (1µM)

26.55 ± 3.44*

40.35 ± 3.73*

51.75 ± 4.56*

55.83 ± 3.90*

50.33 ± 2.20*

S-NONOate (5µM)

34.90 ± 5.14*

47.72 ± 4.68*

58.70 ± 4.35*

59.38 ± 4.03*

59.33 ± 2.9*

The results expressed as mean ± SE, n = 12. *P < 0.05 shows significant difference from control (n = 6–8).
Table 4. The suppressive effect of S-NONOate (1 µM) on contractions to EFS (2–64 Hz, 50 V, 0.5 ms) in mouse
corpus cavernosum.
EFS

2

4

8

16

32

64 Hz

Control

1.60 ± 1.2

5.95 ± 1.32

17.55 ± 3.1

40.55 ± 2.58

68.35 ± 1.39

92.45 ± 1.62

S-NONOate

0.25 ± 0.25*

0.75 ± 0.25*

0.50 ± 0.28*

1.0 ± 0.1*

14.4 ± 4.2 *

78.2 ± 4.1

The results are presented as mean ± SE, n = 8. *P < 0.05 shows significant difference from control (n = 6–8).

significant inhibition on the contractions. Administration
of L- NOARG results in an EFS-induced contraction
beginning immediately after initiation of the stimulus and
increased the magnitude and duration of the contraction in
the corpus cavernosum tissue (28). It is suggested that lack
of contractile response during stimulation is due to release
of nitric oxide, which also modulates the magnitude of
the contraction (28–30). It was also shown that treatment
with ODQ enhanced the nerve-evoked contractions,
whereas zaprinast, a cGMP-phosphodiesterase inhibitor,
decreased the contractile response to EFS (28). In this
tissue, S-NONOate may affect the contractile mechanism
of the tissue by generating some nitric oxide-like species
thus activating soluble guanylate cyclase.
0
*
*

20
% Relaxation

Hydroxocobalamin (15,16,21) significantly inhibited
the relaxations to S-NONOate and SNP. This finding
may suggest that direct NO-dependent sGC activation by
S-NONOate plays a critical role in the relaxant activity of
the substance. On the other hand, pyrogallol, a superoxide
generating agent (22) and putative indirect nitric oxide
scavenger (16), did not affect relaxations induced by
S-NONOate or SNP. These findings are consistent with
our previous studies (16). It was suggested that pyrogallol
could not penetrate into cells (23). Therefore, it can be said
that S-NONOate generates NO near or at the membrane.
Moreover, the finding that DETCA, an irreversible
inhibitor of Cu2+- Zn2+ superoxide dismutase found in
cytosol, did inhibit relaxations produced by S-NONOate
and SNP supports this suggestion (16,24,25).
In the present study, S-NONOate had a significant
effect on the EFS-induced nitrergic relaxations that were
completely inhibited by ODQ or L-NOARG (15,26).
S-NONOate potentiated the relaxations to EFS. This
result may suggest that S-NONOate does not synergize
with endogenous nitric oxide and release of the NO from
the S-NONOate compound potentiates the nitrergic
relaxations via sGC activation in mice corpus cavernosum.
On the other hand, some papers suggested that NO donors,
NCX-911 or FPTO (4,7-dimethyl-1,2,5-oxadiazolo[3,4-d]
pyridazine 1,5,6-trioxide) did not affect the nitrergic
relaxations induced by EFS (14,27).
We also investigated the effect of S-NONOate
and SNP on the neurogenic contractions induced by
EFS. S-NONOate and SNP inhibited the neurogenic
contractions in a dose-dependent manner in the medium
containing L-NOARG. S-NONOate and SNP caused a

40

*
*

*
*
*

60
80

100
120

*

*
*

Control
Oral Sildenafil (30 mg/kg)

*
*

*
*

Oral Sildenafil (60 mg/kg)
–7

–6
–5
Log [S-NONOate]

–4

Figure 3. The potentiated effects of oral sildenafil treatment (30
or 60 mg/kg) on the relaxations to S-NONOate (0.1–100 µM) in
mouse corpus cavernosum. Results are expressed as mean ± SE
(n = 6–8). *P < 0.05 shows significant difference from control.
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Table 5. The potentiated effects of oral sildenafil treatment on the relaxations to EFS in mouse corpus
cavernosum.
EFS

2

4

8

16

32 Hz

Control

20.1 ± 3.4

30.9 ± 4.3

40.4 ± 3.9

43.4 ± 3.8

38.3 ± 2.0

Sildenafil (30 mg/kg)

24.1 ± 2.6

35.9 ± 3.1

43.4 ± 2.7

47.6 ± 3.1

41.1 ± 1.3

Sildenafil (60 mg/kg)

35.1 ± 4.6*

48 ± 5.7*

57.9 ± 5.4*

62.1 ± 6.1*

55.0 ± 3.9*

The results are expressed as mean ± SE, n = 8. *P < 0.05, shows significant difference from control (n = 6–8).

Oral sildenafil treatment significantly enhanced the
relaxant responses to EFS and S-NONOate in the mouse
corpus cavernosum. Both S-NONOate and sildenafil
increased the magnitude of nitrergic relaxations with
similar potencies in the tissues. It was shown that sildenafil
enhanced the nitrergic relaxations in the previous papers
(27,31). It is also well known that the action of sildenafil
in corpus cavernosum is dependent on the activation of
the NO-cGMP system (5). Release of the NO from the
S-NONOate or nitrergic nerves stimulated with EFS causes
a sGC activation that results in enhanced cGMP levels.
These results suggest that the combination of sildenafil
and S-NONOate elicits a synergic effect in the erectile
function. On the other hand, we used a commercial
sildenafil preparation that contained some additives and
preservatives. Therefore, it is possible that these additives
and preservatives contributed to the effect.

Our results show that S-NONOate can relax mouse
corpus cavernosum and the relaxant activity of this
agent is soluble guanylate cyclase-dependent. This effect
could be potentiated by sildenafil. The mechanism of the
potentiating effect of sildenafil on the relaxant responses
of S-NONOate may apparently involve nitric oxidedependent activation of soluble guanylate cyclase in
the tissue. Therefore, S-NONOate may be a novel way
of treating male erectile dysfunction in patients with
impaired endogenous nitric oxide production.
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